Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T, Allard M, Oger R, Benlalam H, Raingeard de la Blétière D, Coutolleau A, Preisser L, Desfrançois J, Khammari A, Dréno B, Labarrière N, Delneste Y, Guardiola P, Gervois N. Parrot T, et al. Among authors: dreno b. Eur J Immunol. 2016 Jul;46(7):1770-82. doi: 10.1002/eji.201546061. Epub 2016 May 6. Eur J Immunol. 2016. PMID: 27094152 Free article.
CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells.
Parrot T, Oger R, Benlalam H, Raingeard de la Blétière D, Jouand N, Coutolleau A, Preisser L, Khammari A, Dréno B, Guardiola P, Delneste Y, Labarrière N, Gervois N. Parrot T, et al. Among authors: dreno b. Oncoimmunology. 2016 Oct 28;5(12):e1250991. doi: 10.1080/2162402X.2016.1250991. eCollection 2016. Oncoimmunology. 2016. PMID: 28123891 Free PMC article.
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.
Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A. Frazao A, et al. Among authors: dreno b. Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2. Cancer Immunol Res. 2017. PMID: 28576831
An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.
Charles J, Chaperot L, Hannani D, Bruder Costa J, Templier I, Trabelsi S, Gil H, Moisan A, Persoons V, Hegelhofer H, Schir E, Quesada JL, Mendoza C, Aspord C, Manches O, Coulie PG, Khammari A, Dreno B, Leccia MT, Plumas J. Charles J, et al. Among authors: dreno b. Oncoimmunology. 2020 Apr 12;9(1):1738812. doi: 10.1080/2162402X.2020.1738812. eCollection 2020. Oncoimmunology. 2020. PMID: 32313721 Free PMC article. Clinical Trial.
A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.
Chevallier P, Saiagh S, Dehame V, Guillaume T, Peterlin P, Bercegeay S, Le Bris Y, Bossard C, Gauvrit I, Dreno B, Juge-Morineau N, Béné MC, Gregoire M. Chevallier P, et al. Among authors: dreno b. Hum Vaccin Immunother. 2021 Oct 3;17(10):3511-3514. doi: 10.1080/21645515.2021.1943991. Epub 2021 Jun 21. Hum Vaccin Immunother. 2021. PMID: 34152898 Free PMC article. Clinical Trial.
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. van Baren N, et al. Among authors: dreno b. J Clin Oncol. 2005 Dec 10;23(35):9008-21. doi: 10.1200/JCO.2005.08.375. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061912 Clinical Trial.
808 results